


## Supplementary Information

**Table S1:** The primers used in qPCR are listed in table.


Primers	Sequences (5' to 3')	Amplicon (bp)
CSFV-RT	CTAGCCATGCCCACAGTAGGA CTCCATGTGCCATGTACAGCA	286
APOH-RT	CAGTTTCACTTGCAACCGGG TCCAAACATTGCGTGCTGTG	229
ABCA1-RT	CGACAATGTGGAGAGGACGAA GCCAGTTTTCTTCTCCATACCC	169
APOE-RT	CACCGAGGACCTGCAGAAG CAACTGGCTGCCCTGCTC	223
DHCR24-RT	CGGCAAGTCCTCAAGTCCTC AGTCCCTGAGTACCCACAGT	132
DHCR7-RT	TGTGGTTCGCTAACTCCCAC ATCATGGCGAAGGTGGAGAC	121
FDFT1-RT	AGTTCTACAATCTGCTGCGCT CTGGATAACGGCTGCGAAAC	143
HMGCS1-RT	GAGCCGTGCCAAGTTGCG CAGCAGCTACACCGTCGTATT	275
HMGCR-RT	TCGCAGATGGCATGACTCGT CTGACCTGGACTGGAAACGG	204
HSD17B7-RT	TGGACTTCACCTGTGCTTGG GAACACCGATGACAAGCTGC	133
LIPG-RT	TCTATTGCTGTTTTGCGGCG ATGCCACTCATCGTCCATCC	253
SREBP2-RT	AGGTCCCGTTACCTTCCTTCT GTCACCAGGCTTTGGACTTG	289
IRF3-RT	ACACCCTCTGGTTCTGCATG GGCTGTTGGAAATGTGCAGG	171
IRF7-RT	GACTTCGGCACCTTCTTCCA AGGACGAGGCTCTTCTCCTT	134
CCL2-RT	AGAAGATCTCGATGCAGCGG TTCTGCTTGGGTCTGCACA	121
CXCL10-RT	CTCTCCAGAACTGTTGCTGT TCAACATGTGGGCAAGATTGAC	113
IFNB1-RT	TGGCAITGCAGAAGCTCCTG ATGCCGAAGATCTGCTGGAG	163
MX1-RT	ATCTCCAGCCACATCCCTCT CTCTTGTCGCTGGTGTCACT	146
MX2-RT	AACGGACCGTCTCCTGTTTC TGAATGGGATCTGGTTGGCC	100
GAPDH-RT	ATCCTGGGCTACACTGAGGA TGTCGTACCAGGAAATGAGCT	146

**Table S2:** The primary and secondary antibodies are listed in table.


Antibodies	Host	Dilutions	Supplier
CSFV Envelope glycoprotein E2 Antibody	Rabbit	1:1000	Bioss
LDLR Monoclonal antibody	Mouse	1:1000	Proteintech
Anti-PCSK9 Antibody	Rabbit	1:1000	BOSTER
Phospho-TBK1/NAK Antibody	Rabbit	1:1000	Beyotime
TBK1 Rabbit Polyclonal Antibody	Rabbit	1:1000	Beyotime
$\beta$ -Actin Mouse Monoclonal Antibody	Mouse	1:1000	Beyotime
HRP-labeled Goat Anti-Mouse IgG(H+L)	Goat	1:1000	Beyotime
HRP-labeled Goat Anti-Rabbit IgG(H+L)	Goat	1:1000	Beyotime
Goat Anti-Rabbit IgG H&L (Alexa Fluor® 488)	Goat	1:1000	Abcam



**Figure S1. (a–b)** Starvation treatment increased dil-LDL uptake,  $n = 3$ , \*\*\*\* $p < 0.0001$ . **(c)** Construction and efficiency detection of LDLR-KO gene editing system. **(d–f)** The disruption of LDLR had no any effect on intracellular cholesterol levels,  $n = 3$ , \*\* $p < 0.01$ , \*\*\* $p < 0.001$ . (WT, wild-type; LO, *ldlr*-ko; MFI, mean fluorescent intensity)



**Figure S2. (a)** Cholesterol biosynthesis schematic diagram. **(b–c)** Construction and efficiency detection of *SQLE* and *HSD17B7* gene editing system.



**Figure S3. (a–h)** The expression of ISGs and p-TBK1 was decreased in CSFV-infected PK-15 cells, and the disruption of cholesterol biosynthesis obviously enhanced type I IFN signaling,  $n = 3$ ,  $*p < 0.05$ ,  $**p < 0.01$ ,  $***p < 0.001$ ,  $****p < 0.0001$ . (WT, wild-type; SO, sqle-ko; Rel. expr, relative expression)